Avid Bioservices Inc (CDMO)

[entdoc]

rrdog, agree, listening to Thorpe's NYU talk once or twice should be routine DD, but a slow sled for non-scientists. It's great that his thinking has your (and my) endorsement as "the real deal". I continue to be a bit surprised by Thorpe's answer, "they are all pretty sick", when asked which patient subset benefited more from Bavi. IMO huge value resides in increased efficacy in less ill patients. Stated in the opposite, it is known that many of the most severely ill patients in clinical trials have immune systems that are in advanced states of collapse. I suppose the answer is, "we haven't been given the chance to try it in less ill patients." I hope that day comes soon.